News

Luna Labs Launches 3 Waves Venture Spinout to Commercialize Advanced Vestibular Stimulation Technology

Luna Labs today announced the launch of 3 Waves, Inc. (“3Waves”), a dual-use spinout company that was established to commercialize advanced virtual and mixed reality technologies for defense, commercial simulation, and medical applications.

As part of the spinout, 3Waves and Mayo Clinic executed an exclusive license to support the development of next-generation vestibular stimulation systems designed to enhance human performance in virtual and mixed reality environments. With this collaboration, 3Waves has developed a proprietary vestibular interface platform capable of translating inputs from VR/XR simulators into true physical sensations, creating virtual motion.

“We believe the future of immersive technology is a full sensory coherence between the digital environment and human perception. 3Waves represents a major step towards that future by enabling direct vestibular integration with virtual environments to create virtual motion,” said David Remer, Head of Engineering at 3Waves. “We see this as the missing physiological interface layer that has, in many ways, limited XR adoption for years. We are excited to advance that capability and bring it into commercial markets.”

Luna Labs’ efforts on 3Waves technology is part of a broader strategy that is focused on transitioning high potential technologies into scalable standalone businesses positioned for long term growth. “Starting 3Waves is a great example of the Luna Labs commercialization model. This technology started with Phase I SBIR funding, matured with a Phase III contract and internal resources, and we are now positioning it to stand on its own,” said James Garrett, CEO of Luna Labs.

Read more here.

Recent News

07/23/2026

Activation Capital Expands the Bio+Tech Center, Doubling Laboratory Capacity to Strengthen Virginia’s Life Sciences Entrepreneurship and Innovation Ecosystem

Activation Capital, the operating name of the Virginia Biotechnology Research Partnership Authority, today announced an expansion of its Bio+Tech Center to support the continued growth of life sciences entrepreneurship across the region. Activation Capital’s Bio+Tech Center is a life sciences incubator located within the Virginia Bio+Technology Research Park. Serving as both a physical and programmatic

07/22/2026

Epidarex Announces Leadership Appointments

With the launch of our latest fund, Epidarex Capital IV, LP, we are pleased to announce several promotions. As we continue to grow and deepen our impact across the US and UK life science ecosystems, recognizing and elevating exceptional talent within our team is a vital part of that journey. These transitions reflect our continued

07/22/2026

Phlow Corp. Appoints Sripathy Venkatraman, Ph.D, As Chief Scientific Officer

Phlow Corp., a U.S.-based advanced pharmaceutical contract development and manufacturing organization (CDMO), dedicated to strengthening the nation’s pharmaceutical supply chain and protecting America’s medicine cabinet, today announced the appointment of Sripathy Venkatraman, Ph.D., MBA, as Chief Scientific Officer. Venkatraman brings more than 25 years of experience in pharmaceutical development, process chemistry, manufacturing, and scientific leadership. He